{
  "extraction_metadata": {
    "timestamp": "2025-10-04T14:15:41.440683",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 11,
    "total_picos": 36,
    "temperature": 0.1
  },
  "picos_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "PICOs": [
        {
          "Population": "adults with HCC in Barcelona Clinic Liver Cancer (BCLC) stage B or C who did not receive any prior systemic therapy for the advanced or inoperable disease. Hepatic cirrhosis of any aetiology was not an exclusion criterion. Patients in BCLC stage B had to be ineligible for transarterial chemoembolization (TACE). Further inclusion criteria were Child-Pugh stage A and an Eastern Cooperative Oncology Group – Performance Status (ECOG-PS) score of 0 or 1.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE + Sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Best Supportive Care",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "local hepatic therapies",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation with no evidence of extrahepatic disease",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "liver-directed therapies",
          "Outcomes": ""
        },
        {
          "Population": "patients with intermediate-stage hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "supportive care",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 2864
    },
    "CZ": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "CZ",
      "PICOs": [],
      "ChunksUsed": 1,
      "ContextTokens": 202
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "adults with HCC in Barcelona Clinic Liver Cancer (BCLC) stage B or C who did not receive any prior systemic therapy for the advanced or inoperable disease. Hepatic cirrhosis of any aetiology was not an exclusion criterion. Patients in BCLC stage B had to be ineligible for transarterial chemoembolization (TACE). Further inclusion criteria were Child-Pugh stage A and an Eastern Cooperative Oncology Group – Performance Status (ECOG-PS) score of 0 or 1.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE + Sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "HCC patients with PVT",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE",
          "Outcomes": ""
        },
        {
          "Population": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best supportive care",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 2776
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "PICOs": [
        {
          "Population": "patients with unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "Treatment naive adult (aged ≥18 years) patients with advanced, unresectable or metastatic hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "Adult patients with advanced HCC and adult patients with inoperable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 3473
    },
    "EN": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EN",
      "PICOs": [
        {
          "Population": "adults with advanced or unresectable HCC in adults who have not had previous systemic treatment, only if: • they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "adults with advanced or unresectable HCC in adults who have not had previous systemic treatment, only if: • they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 2921
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "PICOs": [
        {
          "Population": "patients with unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        },
        {
          "Population": "Patients aged 18 years or older and diagnosed with locally advanced or metastatic and/ or unresectable HCC with histological/ cytological confirmation or clinical features consistent with the American Association for the Study of the Liver (AASLD) criteria in cirrhotic patients",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "advanced or unresectable hepatocellular carcinoma that has not previously been treated with any other systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "advanced or unresectable hepatocellular carcinoma that has not previously been treated with any other systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab plus bevacizumab",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced and/ or unresectable hepatocarcinoma, Child-Pugh EMI, in the absence of grade 0 or grade 3-4",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced and/ or unresectable hepatocarcinoma, Child-Pugh EMI, in the absence of grade 0 or grade 3-4",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab plus bevacizumab",
          "Outcomes": ""
        },
        {
          "Population": "patients with Child- Pugh C or Child-Pugh B with decompensations associated with poor prognosis such as refractory ascites, recurrent hepatic encephalopathy, spontaneous bacterial peritonitis, etc.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best supportive care",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 4004
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "PICOs": [
        {
          "Population": "adult patients with advanced or unresectable hepatocellular carcinoma (HCC) (stage BCLC B or C) who have not received prior systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 4089
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "PICOs": [
        {
          "Population": "patients with advanced hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        },
        {
          "Population": "patients with hepatocellular carcinoma in whom initiation of curative treatment or (continuation) of locoregional or local palliative treatment is not possible or considered medically inappropriate (hepatocell carcinomas)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best care regimen available",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 3058
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "PICOs": [],
      "ChunksUsed": 15,
      "ContextTokens": 3684
    },
    "PT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PT",
      "PICOs": [
        {
          "Population": "adult patients with advanced or non-resectable hepatocellular carcinoma (HCC) and who have not received any previous systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 2489
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "PICOs": [
        {
          "Population": "adult patients with advanced or non-resettable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Tecentriq (atezolizumab) plus bevacizumab",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced or non-resettable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced or non-resettable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Lenvima (lenvatinib)",
          "Outcomes": ""
        },
        {
          "Population": "patients with HCC having a non viral etiology",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Tecentriq plus bevacizumab",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 3594
    }
  }
}